ChesebroJ.H.FusterV.ElvebackL.R., Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. New England Journal of Medicine, 1984, 310, 209–214.
3.
GoldmanS.CoplandJ.MoritzT., Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. Circulation, 1989, 80, 1190–1197.
4.
FergusonJ.J., Research news: Second European Stroke Prevention Study. Circulation, 1996, 93, 399.
5.
SaniadabiA.R.FisherT.C.McLarenM.BelchJ.F.ForbesC.D., Effect of dipyridamole alone and in combination with aspirin on whole blood platelet aggregation, PGI2 generation and red cell deformability ex vivo in man. Cardiovascular Research, 1991, 25, 177–183.
6.
FitzGeraldG.A., Dipyridamole. New England Journal of Medicine, 1987, 316, 1247–1257.
7.
De La CruzJ.P.GarciaP.J.De La CuestaF. Sanchez, Dipyridamole inhibits platelet aggregation induced by oxygen-derived free radicals. Thrombosis Research, 1992, 66, 277–285.
8.
BultH.FretH.R.JordaensF.R.HermanA.G., Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide. European Journal of Pharmacology, 1991, 199, 1–8.
9.
GantmacherM.L., Antiplatelet agents: A review. Journal of Royal Society of Medicine, 1979, 72, 513–519.
10.
HarkerL.A., Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Circulation, 1986, 73, 206–223.
11.
PantelyG.A.GoodnightS.H.RahimtoolaS.H., Failure of antiplatelet and antiplatelet and anticoagulation therapy to improve patency of grafts after coronary artery bypass: A controlled, randomized study. New England Journal of Medicine, 1979, 301, 962–966.
12.
SharmaG. V.KhuriS. F.JosaM.FollandE. D.ParisiA. F., The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency. Circulation, 1983, 68 (Suppl. II), S218–S221.
13.
ChesebroJ.H.ClementsI.P.FusterV., A platelet-inhibitor-drug trial in coronary artery bypass operations. Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. New England Journal of Medicine, 1982, 307, 73–78.
14.
HendersonW.G.GoldmanS.CopelandJ.G.MoritzT.E.HarkerL.A., Antiplatelet or anticoagulant therapy after coronary artery bypass surgery. A meta-analysis of clinical trials. Annals of Internal Medicine, 1989, 111, 743–750.
15.
GoldmanS.CoplandJ.MoritzT., Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: Results of a Veterans Administration Cooperative Study. Circulation, 1988, 77, 1324–1332.
16.
EkestromS.A.GunnesS.BrodinU.B., Effect of dipyridamole (persantin) on blood flow and patency of aortocoronary vein bypass grafts. Scandinavian Journal of Cardiovascular Surgery, 1990, 24, 191–196.
17.
Van Der MeerJ.HillegeH.L.KootstraW., For the CABADAS research group of the Interuniversity Cardiology Institute of the Netherlands, Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: A comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. Lancet, 1993, 342, 257–264.
18.
SanzG.PajaronA.AlegriaE., Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Circulation, 1990, 82, 765–773.
19.
Van Der MeerJ.De La RiviereA. BrutelVan GilstY.M., Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole and oral anticoagulant agents after internal mammary artery bypass grafting: Patency and clinical outcome at 1 year. Journal of the American College of Cardiology, 1994, 24, 1181–1188.
20.
AgnewT.M.FrenchJ.K.NeutzeJ.M., The role of dipyridamole in addition to low dose aspirin in the prevention of occlusion of coronary artery bypass grafts. Australian and New Zealand Journal of Medicine, 1992, 22, 665–676.
21.
SchwartzL.BourassaM.G.LesperanceJ., Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. New England Journal of Medicine, 1988, 318, 1714–1719.
22.
BarthananE.S.SchwartzJ.S.TaylorL., Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation, 1987, 76, 125–134.
23.
LemboN.J.BlackM.R.RoubinG.S., Effect of pretreatment with aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. American Journal of Cardiology, 1990, 65, 422–426.
24.
MokC.K.BoeyJ.WangR., Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: A prospective randomised trial. Circulation, 1985, 72, 1059–1063.
25.
SullivanJ.M.HarkenD.E.GorlinR., Pharmacologic control of thromboembolic complications of cardiac valve replacement. New England Journal of Medicine, 1971, 284, 1391–1394.
26.
ChesebroJ.H.FusterV.ElvebackL.R., Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole. American Journal of Cardiology, 1983, 51, 1537–1541.
27.
TurpieA.G. G.GentM.LaupacisA., A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. New England Journal of Medicine, 1993, 329, 524–529.
28.
SinghJ.P.RothfassM.WiernickiT.R., Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: Implications in the treatment of restenosis after angioplasty. Journal of the College of Cardiology, 1994, 23, 665–671.
29.
MiuraT.OgawaT.IwamotoT.ShimamotoK.IimuraO., Dipyridamole potentiates the myocardial infarct size-limiting effect of ischaemic preconditioning. Circulation, 1992, 86, 979–985.
30.
KogaY.KiharaK.YamaguchiR.WadaT.ToshimaH., Therapeutic effect of oral dipyridamole on myocardial perfusion and cardiac performance in patients with hypertrophic cardiomyopathy. American Heart Journal, 1992, 123, 433–438.
